Coherus Oncology, Inc.
CHRS Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$1.07
KIRA · Stoqly’s AI analyst, in plain words
- Coherus Oncology, Inc. had $42.2M of revenue in fiscal 2025, up 59.8% on the year before. Over five years, revenue changed −38.4% a year on average.
- Its operating margin was −429.5%, up 327.1 pts: of every 100 in sales, about −430 is left after running the business.
- Coherus Oncology, Inc. made $168M of net profit in fiscal 2025.
Market cap
$166M
P/E
—
Revenue
$42.2M
Net income
$168M
Free cash flow
—
Operating margin
−429.5%
Coherus Oncology, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+59.8%
Yes. Sales grew 59.8% last year.
Does it make a profit?
398.4%
Yes. It keeps 398.4% of every sale as profit.
How healthy are the accounts?
5 / 8
Mixed. It passes 5 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Coherus Oncology, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 9, 2026
- Legal name
- Coherus Oncology, Inc.
- CIK
- 0001512762
Coherus Oncology, Inc. · CHRS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $327M | $211M | $257M | $26.4M | $42.2M |
| Revenue growth | −31.4% | −35.4% | 21.9% | −89.7% | 59.8% |
| Gross margin | 82.4% | 66.8% | 38.2% | 66.9% | 67.2% |
| Operating margin | −80.8% | −121.7% | −79.0% | −756.6% | −429.5% |
| Net income | −$287M | −$292M | −$238M | $28.5M | $168M |
| Net margin | −87.9% | −138.2% | −92.5% | 108.0% | 398.4% |
| Diluted EPS | −$3.81 | −$3.76 | −$2.53 | $0.25 | $1.43 |
| Cash | |||||
| Cash from operations | −$37.4M | −$241M | −$175M | −$20.4M | −$139M |
| Capital expenditure | $1.3M | $2.0M | $0.3M | — | — |
| Free cash flow | −$38.7M | −$243M | −$175M | — | — |
| FCF margin | −11.9% | −115.2% | −68.1% | — | — |
| Share count change | −9.6% | 2.9% | 21.3% | 21.7% | 2.3% |
| Debt and strength | |||||
| Cash and short-term investments | $417M | $192M | $118M | $126M | $172M |
| Shareholders' equity | $97.7M | −$137M | −$193M | −$132M | $61.0M |
| Current ratio | 3.6x | 2.7x | 1.4x | 1.2x | 1.5x |
| Interest coverage | −11.5x | −7.9x | −5.0x | −18.6x | −20.1x |
| Returns and quality | |||||
| Return on equity | −151.6% | — | — | — | — |
| Return on tangible equity | −307.8% | — | — | — | 409.7% |
| Piotroski F-score | 2 | 1 | 2 | 3 | 5 |
| Altman Z'' | −3.3 | −9.6 | −9.1 | −13.6 | −20.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Coherus Oncology, Inc. · CHRS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.07 a share, the company is worth $166M.
Source: SEC EDGAR XBRL filings (CIK 0001512762). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.